Malignant mixed mullerian tumour of the ovary: Prognostic factor and response of adjuvant platinum-based chemotherapy

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 43, Issue 1, 2003, Pages 61-64

  Inthasorn, Perapong ^a,b   Beale, Philip ^b   Dalrymple, Christopher ^b,c   Carter, Jonathan ^b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adjuvant chemotheraphy; Cytoreduction; Malignant mixed mullerian tumour of the ovary; Platinum; Prognostic factors

Indexed keywords

CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MEDROXYPROGESTERONE ACETATE; PLATINUM DERIVATIVE; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; GYNECOLOGY; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; MIXED MULLERIAN TUMOR; OVARIECTOMY; OVARY CANCER; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; HYSTERECTOMY; MIXED TUMOR, MULLERIAN; OVARIAN NEOPLASMS; OVARIECTOMY; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0038633611     PISSN: 00048666     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0004-8666.2003.00003.x     Document Type: Article

References (18)

1. Wei LH, Huang CY, Cheng SP, Chen CA, Hsieh CY. Carcinosarcoma of ovary associated with previous radiotherapy. Int J Gynecol Cancer. 2001; 11: 81-84.
2. Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcoma. Gynecol Oncol. 1989; 32: 228-232.
3. DiSilvestro PA, Gajewski WH, Ludwig ME, Kourea H, Sung J, Granai CO. Malignant mixed mesodermal tumors of the ovary. Obstet Gynecol. 1995; 86: 780-782.
4. Ariyoshi K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immnunohistochemical analysis of 23 cases. Histopathology. 2000; 37: 427-436.
5. Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group Study. Gynecol Oncol. 1984; 18: 278-292.
6. Muntz HG, Jones MA, Goff BA et al. Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer. 1995; 76: 1209-1213.
7. Sood AK, Sorosky JI, Gelder MS et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer. 1998; 82: 1731-1737.
8. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstet Gynecol. 1995; 85: 735-739.
9. Berek JS. Epithelial ovariran cancer. In: Berek JS, Hacker NF (eds). Practical gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins, 2000; 457-522.
10. Dictor M. Malignant mixed mesodermal tumor of the ovary: a report of 22 cases. Obstet Gynecol. 1985; 65: 720-724.
11. Sutton GP, Blessing JA, Homesley HD, Malfetano JH. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group Stydy. Gynecol Oncol. 1994; 53: 24-26.
12. Le T, Krepart GV, Lotocki RJ, Heywood MS. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience. Gynecol Oncol. 1997; 65: 237-240.
13. Morrow CP, Bundy BN, Hoffman J, Sutton G, Homesley H. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1986; 9: 24-26.
14. Sit AS, Price FV, Kelly JL et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol. 2000; 79: 196-200.
15. Chauveinc L, Deniaud E, Plancher C et al. Uterine sarcoma: the Curie Institut experience. Prognostic factor and adjuvant treatments. Gynecol Oncol. 1999; 72: 232-237.
16. Pautier P, Genestie C, Rey A et al. Analysis of clinicopathologic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000; 88: 1425-1431.
17. Barakat RR, Rubin SC, Wong G, Saigo PE, Markman M, Hoskins WJ. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol. 1992; 80: 660-664.
18. Geisler JP, Wiemann MC, Miller GA, Zhou Z, Geisler HE. Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol. 1995; 59: 45-47.